Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HRS8179

Phase 3Small molecule

BBeijing Suncadia Pharmaceuticals Co., Ltd

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Cerebral Edema Following Large Hemispheric InfarctionRecruiting

Severe Cerebral Edema Following Large Hemispheric InfarctionPhase 3

Recruiting

Timeline

Expected Milestones

Q3 2027

Phase 2/3Recruiting

Severe Cerebral Edema Following Large Hemispheric Infarction

NCT06732648

Clinical

Trials by Indication[1]

Trial1 trial

A Trial of HRS8179 on Brain Swelling After Large Hemispheric Infarction

Completed·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 2·NCT05690711·40 enrolled

Severe Cerebral Edema Following Large Hemispheric Infarction1 trial

The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction

Recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 2/3·NCT06732648·725 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HRS8179. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRS8179 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRS8179. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Suncadia Pharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Suncadia Pharmaceuticals Co., Ltd

Related News